Inamoto T, et al. - The target of this analysis was to inspect the biological and prognostic characteristics of concomitant carcinoma in situ (c-CIS), compared with pure/primary CIS tumor (p-CIS). Worse outcome was reported by patients presenting with c-CIS than those with p-CIS. This, in turn, gave rise to a necessity for differentiating both entities in the treatment decision process.

Methods

• Data analysis was performed of the multicenter UTUC database.
• Data cumulated from the Nishinihon Uro-Oncology Group (NUOG), including gender, age, presence of bladder cancer, pT stage, underwent exploratory assessment.
• A comparison was carried out of the clinico-pathological features between various subtypes.
• Cancer specific survival (CSS) and overall survival (OS) and relative excess risk of death were computed through the CIS subtype.

Results

• The eligible candidates comprised of 163 patients with CIS in the upper urinary tract. p-CIS was reported in 24.5% of the enrollees.
• In c-CIS cohort, pathological diagnosis for non-CIS region was discovered to be pTa, pT1, pT2, pT3 and pT4 in 4.9%, 22.8%, 25.2%, 44.7% and 1.6%, respectively.
• Higher sensitivity of selective urine cytology test was determined in the p-CIS group than the c-CIS group (60.0 vs. 37.4%).
• The 10-year estimated mean CSS was 92.4 months (83.7-101.0) for overall CIS cohort, after a median follow-up of 32 months.
• The 10-year estimated mean CSS of p-CIS patients (111.8 months, 101.0-122.6) appeared to be substantially longer than that of c-CIS (85.89 months, 75.3-96.5; Log rank p=0.007).